ヘパリスファーマ株式会社
Tokyo, JP · 2 known investors
Hepalys Pharma is a late-stage biopharmaceutical company developing innovative therapeutics for liver disease in Japanese and Asian patients, focusing on metabolic dysfunction-associated steatohepatitis (MASH) treatment through its lead candidate Lanifibranor.
Investors · 2
Frequently asked questions
- What does ヘパリスファーマ株式会社 do?
- Hepalys Pharma is a late-stage biopharmaceutical company developing innovative therapeutics for liver disease in Japanese and Asian patients, focusing on metabolic dysfunction-associated steatohepatitis (MASH) treatment through its lead candidate Lanifibranor.
- Who are ヘパリスファーマ株式会社's investors?
- ヘパリスファーマ株式会社's investors include Catalys Pacific, Nippon Venture Capital.
- Where is ヘパリスファーマ株式会社 headquartered?
- ヘパリスファーマ株式会社 is headquartered in Tokyo, JP.